AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

AVITA Medical (NASDAQ:RCEL) outlined its strategy at the Morgan Stanley Global Healthcare Conference, highlighting its core RECELL technology, which demonstrated a 36% reduction in hospital length of stay for burn patients, and its expanded acute wound care portfolio including Cohealyx and PermeaDerm. Despite Q1 and Q2 revenue misses attributed to initial uncertainty with a new CPT reimbursement code, the company anticipates full resolution by Q4, projecting 24% year-over-year growth and profitability by Q2/Q3 next year. The firm has optimized its commercial model for higher productivity, is leveraging new NTAP reimbursement for non-burn trauma wounds, and plans international expansion, all underpinned by a strong cash runway.

Analysis

AVITA Medical (RCEL) presents a compelling growth narrative centered on a strategic shift from a single-product entity to a comprehensive acute wound care platform. The core technology, RECELL, is underpinned by significant clinical validation, notably a recent study of 6,300 patients demonstrating a 36% reduction in hospital length of stay, which translates to a powerful economic value proposition for hospitals. While recent financial performance was hampered by a temporary CPT code reimbursement issue that impacted revenue by an estimated $10 million in the first half of the year, management has provided a clear explanation and expects a full resolution by Q4, guiding for a respectable 24% year-over-year growth for the full year. The expansion into a full product suite with Cohealyx and PermeaDerm is critical; although this will lower blended gross margin percentages from RECELL's standalone 87%, it is projected to substantially increase absolute gross profit dollars per procedure without increasing SG&A, creating significant operating leverage. The company has a clear path to profitability, targeting a crossover in Q2 2026, supported by a stable cost structure, sufficient cash reserves, and multiple near-term catalysts including new NTAP reimbursement for non-burn wounds and accelerating adoption of Cohealyx, which is already in the value analysis process at nearly half of U.S. burn centers.

Key Decisions for Investors

• Investors should look past the recent revenue miss, which appears to be a temporary, isolated reimbursement headwind, and instead focus on Q3 and Q4 results for confirmation that demand is rebounding as the CPT code issue resolves.
• The primary metric to monitor is the adoption and revenue contribution from the new portfolio products, Cohealyx and PermeaDerm, as their success is key to validating the company's strategy of increasing gross profit dollars per procedure and achieving its mid-2026 profitability target.
• Consider the 36% reduction in length of stay as the core pillar of the investment thesis, as this provides a powerful, non-discretionary economic incentive for hospital adoption that should drive growth across the entire product suite.
• Given the clear catalysts, including the new NTAP reimbursement effective October 1 and a disciplined international expansion plan, the current valuation may present an attractive entry point for long-term investors, provided management executes on its revised guidance and commercial strategy.